Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TIM-3 does not act as a receptor for galectin-9.
Leitner J, Rieger A, Pickl WF, Zlabinger G, Grabmeier-Pfistershammer K, Steinberger P. Leitner J, et al. PLoS Pathog. 2013 Mar;9(3):e1003253. doi: 10.1371/journal.ppat.1003253. Epub 2013 Mar 21. PLoS Pathog. 2013. PMID: 23555261 Free PMC article.
Immunologisch relevante Aspekte der neuen COVID-19-Impfstoffe : Ein Positionspapier der Österreichischen Gesellschaft für Allergologie und Immunologie (ÖGAI) und des Ärzteverbands Deutscher Allergologen (AeDA).
Untersmayr E, Förster-Waldl E, Bonelli M, Boztug K, Brunner PM, Eiwegger T, Eller K, Göschl L, Grabmeier-Pfistershammer K, Hötzenecker W, Jordakieva G, Moschen AR, Pfaller B, Pickl W, Reinisch W, Wiedermann U, Klimek L, Bergmann KC, Brehler R, Novak N, Merk HF, Rabe U, Schlenter WW, Ring J, Wehrmann W, Mülleneisen NK, Wrede H, Fuchs T, Jensen-Jarolim E. Untersmayr E, et al. Allergo J. 2021;30(5):34-47. doi: 10.1007/s15007-021-4848-z. Epub 2021 Aug 13. Allergo J. 2021. PMID: 34393384 Free PMC article. Review. German. No abstract available.
Reactogenicity and immunogenicity of the second COVID-19 vaccination in patients with inborn errors of immunity or mannan-binding lectin deficiency.
Göschl L, Mrak D, Grabmeier-Pfistershammer K, Stiasny K, Haslacher H, Schneider L, Deimel T, Kartnig F, Tobudic S, Aletaha D, Burgmann H, Bonelli M, Pickl WF, Förster-Waldl E, Scheinecker C, Vossen MG. Göschl L, et al. Front Immunol. 2022 Sep 14;13:974987. doi: 10.3389/fimmu.2022.974987. eCollection 2022. Front Immunol. 2022. PMID: 36189225 Free PMC article.
BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM.
Battin C, Leitner J, Waidhofer-Söllner P, Grabmeier-Pfistershammer K, Olive D, Steinberger P. Battin C, et al. Front Immunol. 2022 Aug 23;13:956694. doi: 10.3389/fimmu.2022.956694. eCollection 2022. Front Immunol. 2022. PMID: 36081508 Free PMC article.
Targeting CD20 in melanoma patients at high risk of disease recurrence.
Pinc A, Somasundaram R, Wagner C, Hörmann M, Karanikas G, Jalili A, Bauer W, Brunner P, Grabmeier-Pfistershammer K, Gschaider M, Lai CY, Hsu MY, Herlyn M, Stingl G, Wagner SN. Pinc A, et al. Mol Ther. 2012 May;20(5):1056-62. doi: 10.1038/mt.2012.27. Epub 2012 Feb 21. Mol Ther. 2012. PMID: 22354376 Free PMC article. Clinical Trial.
96 results